Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 12, 1996, Pages 2824-2828

  Kozawa, Osamu ^a   Uematsu, Toshihiko ^a   Matsuno, Hiroyuki ^a   Niwa, Masayuki ^a   Nagashima, Satoru ^b,c   Kanamaru, Mitsutaka ^c  

^a GIFU UNIVERSITY   (Japan)

^b GEORGETOWN UNIVERSITY   (United States)

^c Shitoro Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BALOFLOXACIN; GREPAFLOXACIN;

ADULT; AGED; AGING; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIVER CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029853190     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.12.2824     Document Type: Article

References (29)

1. Ball, A., C. Fox, M. Ball, R. Brown, and J. Willis. 1986. Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. Antimicrob. Agents Chemother. 29:629-635.
2. Blum, M. D., A. J. Graham, and C. A. McCloskey. 1994. Temafloxacin syndrome: review of 95 cases. Clin. Infect. Dis. 18:946-950.
3. Bruno, R., M. C. Iliadis, B. Lacarelle, V. Cosson, J. W. Mandema, Y. Le Roux, G. Montay, A. Durand, M. Ballereau, and M. Alasia. 1992. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. J. Pharmacokinet. Biopharm. 20:653-669.
4. Chambers, S. T. 1995. Quinolones, N. Z. Med. J. 108:273-277.
5. Child, J., J. M. Andrews, and R. Wise. 1995. Pharmacokinelics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob. Agents Chemother. 39:513-515.
6. Crome, P., and R. J. Flanagan. 1994. Pharmacokinetic studies in elderly people. Are they necessary?. Clin. Pharmacokinet. 26:243-247.
7. Crowley, J., S. Echaves, B. Cusak, and R. Vestal. 1990. The elderly, p. 141-174. In R. Williams, D. Brater, and J. Mordenti (ed.), Rational therapeutics: a clinical pharmacologic guide for the health professional. Marcel Dekker, Inc., New York.
8. Davey, P., and T. McDonald. 1993. Postmarketing surveillance of quinolones, 1990 to 1992. Drugs 45(Suppl. 3):46-53.
9. Iber, F. L., P. A. Murphy, and E. S. Connor. 1994. Age-related changes in the gastrointestinal system. Effects on drug therapy. Drugs Aging 5:34-48.
10. Imada, T., S. Miyazaki, M. Nishida, K. Yamaguchi, and S. Goto. 1992. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob. Agents Chemother. 36:573-579.
11. Ito, T., M. Osuki, and T. Nishino. 1992. In vitro antibacterial activity of Q-35, a new fluoroquinolone. Antimicrob. Agents Chemother. 36:1708-1714.
12. Iwasaki, H., S. Miyazaki, A. Tsuji, K. Yamaguchi, and S. Goto. 1995. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone. Chemotherapy 41:100-112.
13. LeBel, M., G. Barbeau, M. Bergeson, D. Roy, and F. Vallée. 1986. Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacotherapy 6:87-91.
14. Mukai, F., K. Ohmori, H. Tamaoka, M. Kikuchi, H. Akiyama, and M. Odomi. 1995. Methods for the bioassay and high-performance liquid chromatography in body fluids. Jpn. J. Chemother. 43(S-5):91-98.
15. Nakashima, M., T. Uematsu, M. Fukuchi, M. Nakano, and K. Kosuge. 1995. Clinical phase I study of balofloxacin. I. Single oral administration. Jpn. J. Chemother. 43(S-5):115-140.
16. Nakashima, M., T. Uematsu, M. Fukuchi, M. Nakano, and K. Kosuge. 1995. Clinical phase I study of balofloxacin. II. Repeated oral administration. Jpn. J. Chemother. 43(S-5):141-159.
17. Nakashima, M., T. Uematsu, S. Nagashima, K. Kosuge, and M. Kanamaru. 1995. Phase 1 study of grepafloxacin. Jpn. J. Chemother. 43(S-1):155-175.
18. Norrby, S. R., and P. S. Lietman. 1993. Safety and tolerability of fluoroquinolones. Drugs 45(Suppl. 3):59-64.
19. Piddock, L. J. V. 1994. New quinolones and gram-positive bacteria. Antimicrob. Agents Chemother. 38:163-169.
20. Regazzi, M. B., R. Rondanelli, and M. Calvi. 1993. The need for pharmacokinetics protocols in special cases. Pharmacol. Res. 27:21-31.
21. Rowland, M., and T. N. Tozer. 1989. Clinical pharmacokinetics: concepts and applications, 2nd ed. Lea & Febiger, Philadelphia.
22. Salom, I. L., and K. Davis. 1995. Prescribing for older patients: how to avoid toxic drug reactions. Geriatrics 50:37-40.
23. Shah, A., J. Lettieri, D. Nix, J. Wilton, and H. Heller. 1995. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob. Agents Chemother. 39:1003-1006.
24. Sloan, R. W. 1992. Principles of drug therapy in geriatric patients. Am. Fam. Phys. 45:2709-2718.
25. Uematsu, T., and M. Nakashima. 1992. Pharmacokinetic aspects of newer quinolone. Prog. Drug Res. 38:39-55.
26. Uematsu, T., Y. Ohsawa, A. Mizuno, and M. Nakashima. 1994. Analysis of a new fluoroquinolone derivative (0-35) in human scalp hair as an index of drug exposure and as a time marker in hair. Int. J. Leg. Med. 106:237-243.
27. Wakebe, H., and S. Mitsuhashi. 1992. Comparative in vitro activities of a new quirolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob. Agents Chemother. 36:2185-2191.
28. Walker, J., and H. Wynne. 1994. Review: the frequency and severity of adverse drug reactions in elderly people. Age Ageing 23:255-259.
29. Yamaoka, K., Y. Tanigawara, T. Nakagawa, and T. Uno. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J. PharmacobioDyn. 4:879-885.